使用ESMO临床获益量级量表指导癌症药物覆盖与报销的HTA推荐:一项回顾性分析
该回顾性分析提取了六个国家/地区HTA机构2011年1月1日至2020年12月31日间的公开报告,评估67个药物-适应症对(共360份提交)中ESMO-MCBS评分等因素对HTA结局及时间的影响。高ESMO-MCBS评分(4或5分 vs 1-3分)与更短的上市许可至阳性HTA结局间隔(HR 1.42 [95% CI 1.11-1.81], p=0.0055)及更高的阳性结局可能性(无限制RRR 14.10 [3.54-56.20], p=0.0002)相关。
要点
- 高ESMO-MCBS评分(4或5分)与阳性HTA结局可能性增加及间隔缩短相关。
- 平行审评、风险共担协议或特殊资助安排与更短的阳性HTA结局间隔相关。
- 加速上市许可与更长的阳性HTA结局时间相关(HR 0.70 [0.51-0.95], p=0.024)。
核心结论
- 高ESMO-MCBS评分(提示显著临床获益)增加阳性HTA结局的可能性并缩短上市许可至HTA结局的间隔,且该关联不受其他变量影响。
- 证据不确定性和未满足医疗需求等因素也影响HTA结局,且存在国家间差异。
研究设计与样本
- 回顾性分析,数据提取自六个国家/地区(澳大利亚、加拿大、英格兰、法国、加拿大魁北克省、苏格兰)HTA机构的公开报告及相关来源。
- 纳入2011年1月1日至2020年12月31日间已发表ESMO-MCBS评分且至少被三个HTA机构评估的用于非治愈性实体瘤的新癌症药物,共67个药物-适应症对、360份HTA提交。
- 使用ESMO-MCBS评分作为自变量,进行描述性和多变量回归分析。
主要发现
- 高ESMO-MCBS评分(4或5分 vs 1-3分)与更短的上市许可至阳性HTA结局间隔相关(HR 1.42 [95% CI 1.11-1.81], p=0.0055)。
- 平行审评(vs 标准上市许可流程;HR 1.69 [1.13-2.54], p=0.011)、风险共担协议(vs 无资助协议;HR 4.62 [2.51-8.51], p<0.0001)和特殊资助安排(HR 4.16 [2.03-8.50], p=0.0001)与更短的间隔相关。
- 加速上市许可与更长的阳性HTA结局时间相关(vs 标准授权流程;HR 0.70 [0.51-0.95], p=0.024)。
- 高ESMO-MCBS评分与阳性无限制结局(RRR 14.10 [3.54-56.20], p=0.0002)和阳性限制性结局(RRR 4.52 [1.90-10.75], p=0.0006)相关。
- 未满足医疗需求的确认与阳性无限制结局(RRR 22.73 [5.51-93.73], p<0.0001)和阳性限制性结局(RRR 1.87 [1.18-2.97], p=0.0075)相关;经济模型输入不确定性则呈负相关(无限制RRR 0.28 [0.10-0.78], p=0.014;限制性RRR 0.45 [0.25-0.82], p=0.010)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommendations by countries' health technology assessment (HTA) agencies are used to decide which new therapies warrant the allocation of limited health-care resources to make them available through publicly funded health systems. This process is of public health importance for balancing the dual aims of optimising patient outcomes while ensuring financial sustainability. We evaluated which factors affect HTA outcomes and the time to positive HTA outcome, focussing on the role of clinical benefit evaluated with the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). METHODS: In this retrospective analysis, data were extracted from publicly available HTA reports and related sources from six country settings and their respective HTA agencies (Australia, Canada, England, France, the Canadian province of Quebec, and Scotland). We evaluated new cancer medicines for treating solid tumours in a non-curative setting with published ESMO-MCBS scores and that had been assessed by at least three HTA agencies between Jan 1, 2011, and Dec 31, 2020. Using ESMO-MCBS score as an independent variable, we did descriptive and multivariable regression analyses to evaluate: (1) factors associated with the time between marketing authorisation and positive (unrestricted [List] and restricted [List with Constraints]) HTA outcome; and (2) factors associated with HTA outcomes. FINDINGS: 67 medicine-indication pairs used in non-curative settings were identified, totalling 360 HTA submissions (medicine-indication-country triplets) reviewed by the six HTA agencies. Factors significantly associated with a reduced interval between marketing authorisation and a positive (unrestricted or restricted) HTA outcome included a high ESMO-MCBS score (ie, 4 or 5, vs a low or average score of 1-3; hazard ratio [HR] per 1 month increment 1·42 [95% CI 1·11-1·81], p=0·0055), parallel review (vs standard marketing authorisation process; HR 1·69 [1·13-2·54], p=0·011), having a risk-sharing agreement or special funding arrangements (vs no funding agreement, HR 4·62 [95% CI 2·51-8·51], p<0·0001, and HR 4·16 [2·03-8·50], p=0·0001, respectively), and assessment by particular HTA agencies (pan-Canadian Oncology Drug Review vs National Institute for Health and Care Excellence [NICE], HR 2·82 [1·68-4·75], p=0·0001; and Haute Autorité de Santé vs NICE, HR 5·70 [2·87-11·33], p<0·0001). Accelerated marketing authorisation was significantly associated with a longer time to positive HTA outcome (vs standard authorisation process; HR 0·70 [95% CI 0·51-0·95], p=0·024). Positive HTA outcomes (both unrestricted and restricted) were significantly associated with a high ESMO-MCBS score (vs low or average ESMO-MCBS score; relative risk ratio [RRR] 14·10 [95% CI 3·54-56·20], p=0·0002, and RRR 4·52 [1·90-10·75], p=0·0006, respectively) and acknowledgment of unmet medical need (vs unmet need not recorded, RRR 22·73 [5·51-93·73], p<0·0001, and RRR 1·87 [1·18-2·97], p=0·0075, respectively). By contrast, positive HTA outcomes (unrestricted and restricted) were inversely associated with uncertainties regarding inputs to economic models informing HTA submissions (vs uncertainties not recorded, RRR 0·28 [0·10-0·78], p=0·014, and RRR 0·45 [0·25-0·82], p=0·010, respectively). Regarding country-relevant effects, inverse associations with positive HTA outcomes (both unrestricted and restricted) were observed for assessment in Quebec (vs England; RRR 1·15×10-6 [1·44×10-7-9·09×10-6], p<0·0001, and RRR 0·33 (0·24-0·46), p<0·0001, respectively) and for assessment in Australia (vs England; RRR 1·78×10-6 [1·04×10-8-3·00×10-4], p<0·0001, and RRR 0·30 [0·15-0·61], p=0·0008, respectively). INTERPRETATION: Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive HTA outcome and shortened the interval between marketing authorisation and HTA outcome, and this association was not affected by other variables. Additional factors informing HTA outcomes include evidence uncertainties and unmet medical need. Country-relevant differences exist in the time-to-HTA outcome and the propensity of some countries to achieve positive (restricted or unrestricted) outcomes compared with others. FUNDING: None.
引用
- Kanavos P, Visintin E, Angelis A, et al. Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis. Lancet Oncol. 2024. PMID: 39637889. doi:10.1016/S1470-2045(24)00505-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。